ASPE.US Aspen Neuroscience, Inc. Common Stock

Healthcare Biotechnology USA Stocks
12.59 USD
Close of Nov 14, 2026
11.20 15.00
Market cap
USD 366M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is ASPE.US undervalued?

Graham number

The Graham number of Aspen Neuroscience, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aspen Neuroscience, Inc. Common Stock fundamental analysis

No fundamental analysis for Aspen Neuroscience, Inc. Common Stock yet.

Aspen Neuroscience, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aspen Neuroscience, Inc. Common Stock

Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both sporadic and genetic forms of Parkinson's disease, as well as o…

Full company profile